©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2024; 30(36): 4025-4030
Published online Sep 28, 2024. doi: 10.3748/wjg.v30.i36.4025
Published online Sep 28, 2024. doi: 10.3748/wjg.v30.i36.4025
Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of it
Zi-Ning Zhang, Li-Xuan Sang, Department of Gastroenterology, The Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China
Author contributions: Zhang ZN wrote the original draft; Sang LX revised the manuscript; all authors have read and approved the final version of the manuscript.
Supported by The Science and Technology Plan of Liaoning Province , China, No. 2022JH2/101500063.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Li-Xuan Sang, MD, PhD, Professor, Department of Gastroenterology, The Shengjing Hospital of China Medical University, No. 39 Gliding Road, Tiexi District, Shenyang 110022, Liaoning Province, China. sanglixuan2008@163.com
Received: July 21, 2024
Revised: August 24, 2024
Accepted: September 6, 2024
Published online: September 28, 2024
Processing time: 61 Days and 0.9 Hours
Revised: August 24, 2024
Accepted: September 6, 2024
Published online: September 28, 2024
Processing time: 61 Days and 0.9 Hours
Core Tip
Core Tip: The combination of biologic agents or the combination of a biologic agent and a novel small-molecule drug for treating inflammatory bowel disease (IBD) carries certain risks, and some patients are resistant to these drugs. The regulation of the gut microbiota has become a potential treatment for IBD, and the inclusion of fecal bacteria transplantation in dual-targeted treatments for IBD holds great promise.